

23 September 2024

ASX Announcement

Firebrick receives \$0.9 million R&D Tax Incentive

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) is pleased to announce that it has received an RDTI (R&D Tax Incentive) payment of \$919,656 for eligible R&D expenditure incurred in 2023/24.

The incentive payment related to \$2.114 million in reported R&D costs in the FY24 year, primarily associated with the Company's two clinical trials that were completed in the first half of FY24: a Phase 2 COVID-19 study and a Phase 3 common cold study.

"We welcome the valuable injection of non-dilutive funds from the R&D tax incentive" said Dr Peter Molloy, Executive Director of Firebrick Pharma.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator focused on developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has successfully developed a PVP-I nasal spray (Nasodine® Nasal Spray) and filed international trademarks and multiple patents on the product. The Company has also completed six clinical trials that have affirmed the product's safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings. Firebrick is now commercialising Nasodine in international markets, with the product already launched in the United States and Singapore.

Media enquiries:

Heidi Cuthbert +61 411 272 366 heidi.cuthbert@multiplier.com.au Investor enquiries:

Investors@firebrickpharma.com





